MedTrace Logo

Pentoxifylline for Prevention of Contrast Induced Nephropathy in Chronic Kidney Diseased Patients in Intensive Care Unit

NCT07561801 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-05-01

No results posted yet for this study

Summary

The aim of this study is to evaluate the effect of pentoxifylline for control of contrast induced nephropathy in chronic kidney diseased patients in intensive care unit.

Conditions

Interventions

DRUG

Pentoxifylline

Patients received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and 400 mg oral Pentoxifylline (PTX) three times per day \[dose adjustment according to estimated glomerular filtration rate (eGFR)\] from 24 hr before contrast to 48 hr after contrast procedure.

DRUG

Normal saline

Patient received hydration (100ml normal saline every hour (2400ml/day) with closed dynamic monitoring of the blood volume and placebo with same shape and color of Pentoxifylline (PTX) three times per day from 24 hr before contrast to 48 hr after contrast procedure.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07561801 on ClinicalTrials.gov